DNA repair dysregulation from cancer driver to therapeutic target

Nature Reviews Cancer

Volumn 12, Issue 12, 2012, Pages 801-817

  Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; BMN 673; CAMPTOTHECIN; CARMUSTINE; CEP 9722; CETUXIMAB; CRT 0044876; CYCLOSPORIN; DACARBAZINE; DNA METHYLTRANSFERASE; EMBONIC ACID; IC 86621; IC 87361; ICOSAPENTAENOIC ACID; INO 1001; LOMEGUATRIB; LUCANTHONE; METHOXYAMINE; NIRAPARIB; NSC 281680; NU 7026; NU 7441; OLAPARIB; OLEANOLIC ACID; PEMETREXED; RUCAPARIB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE CHECKPOINT; CELL DIVISION; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA REPAIR DYSREGULATION; DRUG SAFETY; DRUG TARGETING; EXCISION REPAIR; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HOMOLOGOUS RECOMBINATION; HUMAN; MELANOMA; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL CYCLE CHECKPOINTS; DNA DAMAGE; DNA REPAIR; HOMOLOGOUS RECOMBINATION; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84870218588     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3399     Document Type: Review

References (197)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011). An excellent review highlighting enabling characteristics, as well as emerging hallmarks, of cancer.
2. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005 (Pubitemid 40558993)
3. Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005) References 2 and 3 show that early in tumorigenesis oncogenic stress activates the DDR, which acts as a temporary barrier to progression, but defects in the DDR eventually arise allowing full-blown cancer to develop. (Pubitemid 40559004)
4. Tubbs, J. L., Pegg, A. E. & Tainer, J. A. DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6 alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair 6, 1100-1115 (2007 (Pubitemid 47058393)
5. Tricker, A. R. & Preussmann, R. Carcinogenic N nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutat. Res. 259, 277-289 (1991
6. Saffhill, R., Margison, G. P. & O'Connor, P. J. Mechanisms of carcinogenesis induced by alkylating agents. Biochim. Biophys. Acta 823, 111-145 (1985 (Pubitemid 16169121)
7. Zaidi, N. H., Liu, L. & Gerson, S. L. Quantitative immunohistochemical estimates of O6 alkylguanine-DNA alkyltransferase expression in normal and malignant human colon. Clin. Cancer Res. 2, 577-584 (1996 (Pubitemid 26099177)
8. Pegg, A. E. Mammalian O6 alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenesis and therapeutic agents. Cancer Res. 50, 6119-6129 (1990 (Pubitemid 20323662)
9. Rabik, C. A., Njoku, M. C. & Dolan, M. E. Inactivation of O6 alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat. Rev. 32, 261-276 (2006 (Pubitemid 44522815)
10. Friedman, H. S. et al. Phase I trial of O6 benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. 16, 3570-3575 (1998). The first clinical trial of a DNA repair inhibitor supported by pharmacodynamic measurement of the impact on O6 methylguanine levels in tumour material. (Pubitemid 28506770)
11. Ranson, M. et al. Lomeguatrib, a potent inhibitor of O6 alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 12, 1577-1584 (2006
12. Watson, A. J. et al. Tumor O6-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib Clin. Cancer Res. 16, 743-749 (2010
13. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B. & Herman, J. G. Inactivation of the DNA repair gene O6 methylguanine-DNAmethyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797 (1999 (Pubitemid 29086728)
14. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005). The demonstration in a study of >200 patients that patients with epigenetic silencing of MGMT had a significantly better response to TMZ and radiotherapy. (Pubitemid 40349502)
15. Lindahl, T. Instability and decay of the primary structure of DNA. Nature 362, 709-715 (1993). Review of the extent of endogenous and environmental damage to DNA, linking it to ageing and cancer. (Pubitemid 23125973)
16. van Loon, B., Markkanen, E. & Hübscher, U. Oxygen as a friend and enemy: how to combat the mutational potential of 8 oxo-guanine. DNA Repair 9, 604-616 (2010
17. Wiseman, H. & Halliwell, B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J. 313, 17-29 (1996 (Pubitemid 26013419)
18. De Vos, M., Schreiber, V. & Dantzer, F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol. 84, 137-146 (2012
19. Schreiber, V., Dantzer, F., Ame, J. C. & de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nature Rev. Mol. Cell Biol. 7, 517-528 (2006 (Pubitemid 44036457)
20. El Khamisy, S. F., Masutani, M., Suzuki, H. & Caldecott, K. W. A requirement for PARP 1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 31, 5526-5533 (2003). An elegant study demonstrating that ADP-ribose polymer formation at the site of the DNA break is necessary to recruit XRCC1, the scaffold protein of BER. (Pubitemid 37441922)
21. Plo, I. et al. Association of XRCC1 and tyrosyl DNA phosphodiesterase Tdp 1 for the repair of topoisomerase I mediated DNA lesions. DNA Repair 2, 1087-1100 (2003 (Pubitemid 39662824)
22. Larsen, E., Meza, T. J., Kleppa, L. & Klungland, A. Organ and cell specificity of base excision repair mutants in mice. Mutat. Res. 614, 56-68 (2007 (Pubitemid 44920331)
23. Sweasy, J. B., Lang, T. & DiMaio, D. Is base excision repair a tumour suppressor mechanism? Cell Cycle 5, 250-259 (2006 (Pubitemid 43213493)
24. Abbotts, R. & Madhusudan, S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev. 36, 425-435 (2010
25. Hirai, K., Ueda, K. & Hayaishi, O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res. 43, 3441-3446 (1983 (Pubitemid 13061611)
26. Zaremba, T. et al. Poly(ADP-ribose) polymerase 1 polymorphisms, expression and activity in selected human tumour cell lines. Br. J. Cancer 21, 256-262 (2009
27. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nature Rev. Cancer 10, 293-301 (2010
28. Taverna, P. et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res. 485, 269-281 (2001). The early identification that inhibition of APE1 endonuclease could increase TMZ cytotoxicity. (Pubitemid 32406283)
29. Luo, M. & Kelley, M. R. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 24, 2127-2134 (2004 (Pubitemid 39166286)
30. Del Rowe, J. D. et al. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int. J. Radiat. Oncol. Biol. Phys. 43, 89-93 (1999 (Pubitemid 29065836)
31. Mohammed, M. Z. et al. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br. J. Cancer 104, 6536-6563 (2011
32. McNeill, D. R. & Wilson, D. M. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol. Cancer Res. 5, 61-70 (2007
33. Bowman K. J., White, A., Golding, B. T., Griffin, R. J. & Curtin, N. J. Potentiation of anticancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors, NU1025 and NU1064. Br. J. Cancer 78, 1269-1277 (1998 (Pubitemid 28495236)
34. Calabrese, C. R. et al. Preclinical evaluation of a novel poly(ADP-ribose) polymerase 1 (PARP 1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J. Natl Cancer Inst. 96, 56-67 (2004). The first demonstration that a potent PARPi could enhance the antitumour activity of IR and topoisomerase I poisons in xenograft models, with complete durable regressions observed in combination with TMZ.
35. Plummer, R. et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923 (2008). The first clinical trial of a PARPi in cancer patients.
36. Plummer, R. et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J. Clin. Oncol. Abstr. 24, 8013 (2006
37. Zhang, Y. W. et al. Poly(ADP-ribose) polymerase and XPF ERCC1 participate in distinct pathways for the repair of topoisomerase I induced DNA damage in mammalian cells. Nucleic Acids Res. 39, 3128-3140 (2011
38. Drew, Y. et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl Cancer Inst. 103, 334-346 (2011
39. Thomas, H. D. et al. Preclinical selection of a novel poly(ADP-ribose) polymerase (PARP) inhibitor for clinical trial. Mol. Cancer Ther. 6, 945-956 (2007 (Pubitemid 46554564)
40. Mehta, M. P. et al. Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. J. Clin. Oncol. Abstr. 30, 2013 (2012
41. Naegeli, H. & Sugasawa, K. The xeroderma pigmentosum pathway: decision tree analysis of DNA quality. DNA Repair 10, 673-683 (2011
42. Andressoo, J. O., Hoeijmakers, J. H. & de Waard, H. Nucleotide excision repair and its connection with cancer and ageing. Adv. Exp. Med. Biol. 570, 45-83 (2005 (Pubitemid 47413186)
43. Koberle, B. et al. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer 70, 551-555 (1997 (Pubitemid 27149639)
44. Usanova, S. et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1 XPF expression. Mol. Cancer 9, 248 (2010
45. Lange, S. S., Takata, K. & Wood, R. D. DNA polymerases and cancer. Nature Rev. Cancer 11, 96-110 (2011
46. Mizushina, Y. et al. 3 O methylfunicone, a selective inhibitor of mammalian Y family DNA polymerases from an Australian sea salt fungal strain. Mar. Drugs 7, 624-639 (2009
47. Dorjsuren, D. et al. A real-time fluorescence method for enzymatic characterization of specialized human DNA polymerases. Nucleic Acids Res. 37, e128 (2009
48. Umar, A. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96, 261-268 (2004 (Pubitemid 38256271)
49. Wu, X., Xu, Y., Chai, W. & Her, C. Causal link between microsatellite instability and hMRE11 dysfunction in human cancers. Mol. Cancer Res. 9, 1443-1448 (2011
50. Ham, M. F. et al. Impairment of double-strand breaks repair and aberrant splicing of ATM and MRE11 in leukemia-lymphoma cell lines with microsatellite instability. Cancer Sci. 97, 226-234 (2006). Demonstration of the impact of MMR defects on the function of HRR pathways.
51. Karran, P. & Bignami, M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 16, 833-839 (1994
52. Fordham, S. E., Matheson, E. C., Scott, K., Irving, J. A. & Allan, J. M. DNA mismatch repair status affects cellular response to Ara C and other anti-leukemic nucleoside analogs. Leukemia 25, 1046-1049 (2011
53. Plumb, J. A., Strathdee, G., Sludden, J., Kaye, S. B. & Brown, R. Reversal of drug resistance in human tumor xenografts by 2? deoxy 5 azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60, 6039-6044 (2000
54. Vilenchik, M. M. & Knidson, A. G. Endogenous DNA double-strand breaks: production, fidelity of repair, induction of cancer. Proc. Natl Acad. Sci. USA 100, 12871-12876 (2003 (Pubitemid 37339992)
55. Shrivastav, M., De Haro, L. P. & Nickoloff, J. A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 18, 134-147 (2008
56. Mahaney, B. L., Meek, K. & Lees-Miller, S. P. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem. J. 417, 639-650 (2009
57. Beucher, A. et al. ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. EMBO J. 28, 3413-3427 (2009
58. McClendon, A. K.& Osheroff, N. DNA topoisomerase II, genotoxicity, cancer. Mutat. Res. 623, 83-97 (2007
59. Rosenzweig, K. E., Youmell, M. B., Palayoor, S. T. & Price, B. D. Radiosensitization of human tumor cells by the phosphatidylinositol3 kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2 M delay. Clin. Cancer Res. 3, 1149-1156 (1997). Early demonstration that PI3K inhibitors that also inhibit purified and cellular DNA-PKcs are radiosensitizers. (Pubitemid 27319761)
60. Boulton, S., Kyle, S. & Durkacz, B. W. Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. Eur. J. Cancer 36, 535-541 (2000 (Pubitemid 30136235)
61. Hardcastle, I. R. et al. Discovery of potent chromen-4 one inhibitors of the DNA-dependent protein kinase (DNA PK) using a small-molecule library approach. J. Med. Chem. 48, 7829-7846 (2005 (Pubitemid 41698821)
62. Shinohara, E. T. et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res. 65, 4987-4992 (2005 (Pubitemid 40827302)
63. Zhao, Y. et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 66, 5354-5362 (2006). The first DNA-PKcs inhibitor that was demonstrated to induce chemosensitization in tumour-bearing mice. (Pubitemid 43844961)
64. Munck, J. M. et al. Chemosensitisation of cancer cells by KU 0060648; a dual inhibitor of DNA PK and PI 3K. Mol. Can. Ther. 11, 1789-1798 (2012
65. Willmore, E. et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103, 4659-4665 (2004 (Pubitemid 38745999)
66. Feeney, K. M., Wasson, C. W. & Parish, J. L. Cohesin: a regulator of genome integrity and gene expression. Biochem. J. 428, 147-161 (2010
67. Saleh-Gohari, N. et al. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol.Cell Biol. 25, 7158-7169 (2005 (Pubitemid 41105912)
68. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nature Rev. Cancer 11, 467-480 (2011
69. Evers, B., Helleday, T. & Jonkers, J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol.Sci. 31, 372-380 (2010
70. Dupré, A. et al. A forward chemical genetic screen reveals an inhibitor of the Mre11 Rad50 Nbs1 complex. Nature Chem. Biol. 4, 119-125 (2008
71. Rass, E. et al. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nature Struct. Mol. Biol. 16, 819-824 (2009
72. Aloyz, R. et al. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia. 18, 409-414 (2004 (Pubitemid 38425852)
73. Choudhury, A. et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol. Cancer Ther. 8, 203-213 (2009
74. Dernheimer, F.A. & Kastan, M,B. Multiple roles of ATM in monitoring and maintaining DNA integrity. Febs Letts. 584, 3675-3681 (2010
75. Kastan, M. B. & Bartek, J. Cell cycle checkpoints and cancer. Nature 432, 316-323 (2004
76. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Struct. Mol. Biol. 17, 688-695 (2010). Novel observation that deletion of a component of NHEJ restores HRR function in BRCA1 mutant cells.
77. Wang, H., Wang, H., Powel, S. N., Iliakis, G. & Wang, Y. ATR affecting cell radiosensitivity is dependent on homologous recombination but independent of non-homologous end joining. Cancer Res. 64, 7139-7143 (2004 (Pubitemid 39331028)
78. Flynn, R. L. & Zou, L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem. Sci. 36, 133-140 (2011
79. Lewis, K. A. et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 65, 7091-7095 (2005 (Pubitemid 41161237)
80. Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166 (2007). Proteomic analysis of phosphorylation networks downstream of DNA damage-activated ATM and ATR that identifies >700 proteins, which confirmed many targets of the DDR pathway and several new ones. (Pubitemid 46877472)
81. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004 (Pubitemid 39665530)
82. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 444, 633-637 (2006 (Pubitemid 44864442)
83. Massague, J. G1 cell cycle control and cancer. Nature 432, 298-306 (2004
84. Cliby, W. A. et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA damaging agents and defects in cell cycle checkpoints. EMBO J. 17, 159-169 (1998). The first demonstration of the potential chemosensitization effect of ATR activation using an ATR kinase-dead dominant-negative approach. (Pubitemid 28041057)
85. Carrassa, L. Broggini, M., Erba, E. & Damia, G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 3, 1177-1181 (2004 (Pubitemid 40268636)
86. Nghiem, P., Park, P. K., Kim, Y. S., Vaziri, C. & Schreiber, S. L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl Acad. Sci. USA 98, 9092-9097 (2001 (Pubitemid 32743874)
87. Garrett, M. D. & Collins, I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharm. Sci. 32, 308-316 (2011
88. Blasina, A. et al. Breaching the DNA damage checkpoint via PF 00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 7, 2394-2404 (2008
89. Zabludoff, S. D. et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7, 2955-2966 (2008
90. Matthews, D. J. et al. Pharmacological abrogation of S phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6, 104-110 (2007 (Pubitemid 46173886)
91. Chen, T., Stephens, P. A., Middleton, F. K. & Curtin, N. J. Targeting the S and G2 checkpoint to treat cancer. Drug Discov. Today 17, 194-202 (2012
92. Sarkaria, J. N. et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59, 4375-4382 (1999 (Pubitemid 29418757)
93. Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nature Struct. Mol. Biol. 18, 721-727 (2011
94. Reaper, P. M. et al. Selective killing of ATM- or p53 deficient cancer cells through inhibition of ATR. Nature Chem. Biol. 7, 428-430 (2011). The first report of a potent and specific small-molecule ATR inhibitor.
95. Peasland, A., et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 105, 372-381 (2011
96. Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating Genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068 (1997). The first paper to identify the potential use of synthetic lethality in cancer. (Pubitemid 27517876)
97. Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285-289(2003
98. Bryant, H. E. et al. Specific killing of BRCA2 deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005 (Pubitemid 40559005)
99. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). References 98 and 99 were the first to demonstrate that PARPis are synthetically lethal with HRR-defective cells and xenografts. (Pubitemid 40559006)
100. Helleday, T. The underlying mechanism for the PARP & BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5, 387-393 (2011
101. Chan, N. et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 70, 8045-8054 (2010
102. Krawczyk, P. M. et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase 1 inhibition. Proc. Natl Acad. Sci. USA 108, 9851-9856 (2011
103. Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519 (2010). Report of the first clinical trial of a PARPi in patients with BRCA-associated tumours, demonstrating a good response rate with minimal toxicity.
104. Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852-861 (2011
105. Mccabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006
106. Sultana, R. et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int. J. Cancer 131, 2433-2444 (2012
107. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in Brca2 mutated cancers. Nature. 451, 1116-1120 (2008). Demonstration of resistance to PARPi and cisplatin in BRCA-mutant cells by virtue of secondary mutations restoring BRCA protein and HRR function. (Pubitemid 351317449)
108. Patel, A. G., Sarkaria, J. N. & Kaufmann, S. H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl Acad.Sci. USA 108, 3406-3411 (2011
109. Adamo, A. et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol. Cell. 39, 25-35 (2010
110. Bartkova, J. et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26, 7414-7422 (2007 (Pubitemid 350158716)
111. Weston, V. J. et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116, 4578-4587 (2010
112. Williamson, C. T. et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase 1 inhibitors. Mol. Cancer Ther. 9, 347-357 (2010
113. Vilar, E. et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 71, 2632-2642 (2011
114. Martin, S. A. et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17, 235-248 (2010
115. Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Med. 17, 875-883 (2011). Demonstration of the synthetic lethality of CDK1 inhibition and PARP inhibition in tumours, whilst sparing normal tissues, in an animal model.
116. Mitchell, C. et al. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Mol. Pharmacol. 78, 909-917 (2010
117. Höglund, A., Strömvall, K., Li, Y., Forshell, L. P. & Nilsson, J. A. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle. 10, 3598-3607 (2011
118. Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 117, 1440-1449 (2007 (Pubitemid 46718432)
119. Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T. & D'Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 8, 24 (2009
120. Gilad, O. et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 70, 9693-9702 (2010
121. Ferrao, P. T. Bukczynska, E. P., Johnstone, R. W. & McArthur, G. A. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 31, 1661-1672 (2011
122. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011). Demonstration that ETS fusion genes, which are transforming events in prostate cancer, AML and Ewing's sarcoma, associate with PARP1 and DNA PK and are synthetically lethal with PARP inhibition.
123. Brenner, J. C. et al. PARP 1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 72, 1608-1613 (2012
124. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012
125. Olaussen, K. A. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl. J. Med. 355, 983-991 (2006 (Pubitemid 44343542)
126. Moeller, B. J. et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin. Can. Res. 17, 2035-2043 (2011
127. Byrski, T. et al. Response to neoadjuvant therapy with cisplatin in BRCA1 positive breast cancer patients. Breast Cancer Res. Treat. 115, 359-363 (2009
128. Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92, 564-569 (2000). Demonstration that BRCA1 may be silenced in non-hereditary breast and ovarian cancers. (Pubitemid 30212318)
129. Jazaeri, A. A. et al. Gene expression profiles of BRCA1 linked, BRCA2 linked, and sporadic ovarian cancers. J. Natl Cancer Inst. 94, 990-1000 (2002 (Pubitemid 34814728)
130. Konstantinopoulos, P. A. et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555-3561 (2010
131. Ahluwalia, A., Hurteau, J. A., Bigsby, R. M. & Nephew, K. P. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol. Oncol. 82, 299-304 (2001 (Pubitemid 32730607)
132. Vollebergh, M. A. Jonkers, J. & Linn, S. C. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell. Mol. Life Sci. 69, 223-245 (2012
133. Willers, H. et al. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol. Cancer Res. 7, 1304-1309 (2009
134. Gaymes, T. J. et al. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica 94, 638-646 (2009
135. Mukhopadhyay, A. et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 16, 2344-2351 (2010
136. Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159-6168 (2010
137. Pantel, K. & Alix-Panabières, C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med. 16, 398-406 (2010
138. Bonner, W. M. et al. H2AX and cancer. Nature Rev. Cancer 8, 957-967 (2008
139. Tanaka, T., Halicka, H. D., Traganos, F., Seiter, K. & Darzynkiewicz, Z. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle. 6, 371-376 (2007
140. Redon, C. E. et al. Histone ?H2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 16, 4532-4542 (2010
141. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009
142. Kummar, S. et al. Phase I study of PARP inhibitor ABT 888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71, 5626-5634 (2011
143. Kummar, S. et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin. Cancer Res. 18, 1726-1734 (2012
144. Almeida, K. H. & Sobol, R. W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair 6, 695-711 (2007 (Pubitemid 46670095)
145. Kurimasa, A. et al. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol. Cell. Biol. 19, 3877-3884 (1999 (Pubitemid 29193847)
146. Zhong, Q. et al. Association of BRCA1 with the hRad50 hMre11 p95 complex and the DNA damage response. Science 285, 747-770 (1999
147. Haince, J. F. et al. PARP1 dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J. Biol. Chem. 283, 1197-1208 (2008
148. Stiff, T. et al. ATM and DNA PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 64, 2390-2396 (2004 (Pubitemid 38523891)
149. Jensen, R. B., Carreira, A. & Kowalczykowski, S. C. Purified human BRCA2 stimulates RAD51 mediated recombination. Nature 467, 678-683 (2010). The first successful purification of full-length BRCA2, demonstrating that it binds RAD51 and promotes the displacement of replication protein A (RPA) on the single-stranded DNA filament that invades the complementary sequence in the sister chromatid.
150. Liu, L. & Gerson, S. L. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res. 12, 328-331 (2006 (Pubitemid 43166117)
151. Jaeckle, K. A. et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. 16, 3310-3315 (1998 (Pubitemid 28481626)
152. Zhang, X. et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res. 65, 722-726 (2005 (Pubitemid 40216429)
153. Zaremba, T. et al. Poly(ADP-ribose) polymerase 1 (PARP 1) parmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem. J. 436, 671-679 (2011
154. Jalal, S., Earley, J. N. & Turchi, J. J. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin. Cancer Res. 17, 6973-6984 (2011
155. di Masi, A. & Antoccia, A. NBS1 Heterozygosity and cancer risk. Curr. Genom. 9, 275-281 (2008 (Pubitemid 351864253)
156. Digweed, M. & Sperling, K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair 3, 1207-1217 (2004 (Pubitemid 38997964)
157. Heikkinen, K., Karppinen, S. M., Soini, Y., Makinen, M. & Winqvist, R. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J. Med.Genet. 40, e131 (2003
158. Giannini, G. et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep. 3, 248-254 (2002 (Pubitemid 34269518)
159. Takemura, H. et al. Defective Mre11 dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J. Biol. Chem. 281, 30814-30823 (2006 (Pubitemid 44582136)
160. Willems, P. et al. Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes Cancer 47, 137-148 (2008
161. Lee, M. N. et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 13, 832-838 (2007
162. Liu, Y. et al. Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. Hum. Mutat. 29, 381-389 (2008 (Pubitemid 351364940)
163. Yan, D. et al. Targeting DNA-PKcs and ATM with miR 101 sensitizes tumors to radiation. PLoS ONE 5, e11397 (2010
164. Berman, D. B. et al. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res. 56, 3409-3414 (1996 (Pubitemid 26251628)
165. Brose, M. S. et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl Cancer Inst. 94, 1365-1372 (2002 (Pubitemid 35154141)
166. Mohindra, A. et al. Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines. Hum. Mol. Genet. 11, 2189-2200 (2002 (Pubitemid 34994007)
167. Kim, N. G. et al. Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability. Cancer Res. 61, 36-38 (2001
168. Rosenberg, P. S., Greene, M. H. & Alter, B. P. Cancer incidence in persons with Fanconi anemia. Blood 101, 822-826 (2003 (Pubitemid 36139345)
169. Marsit, C. J. et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23, 1000-1004 (2004 (Pubitemid 38250946)
170. Thompson, D. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst. 97, 813-822 (2005). An epidemiological study of the cancer incidence and mortality of >1,000 individuals with heterozygous ATM mutations, identifying an increased risk of breast cancer and some other cancer types. (Pubitemid 40909124)
171. Ai, L. et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol. Biomarkers Prev. 13, 150-156 (2004 (Pubitemid 38116634)
172. Antoni, L., Sodha, N., Collins, I. & Garrett, M. D. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nature Rev. Cancer 7, 925-936 (2007 (Pubitemid 350165855)
173. Panda, H. et al. Amino acid Asp181 of 5' flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry 48, 9952-9958 (2009
174. Gao, Z., Maloney, D. J., Dedkova, L. M. & Hecht, S. M. Inhibitors of DNA polymerase ß: activity and mechanism. Bioorg. Med. Chem. 16, 4331-4340 (2008 (Pubitemid 351539042)
175. Kumamoto-Yonezawa, Y. et al. Enhancement of human cancer cell radiosensitivity by conjugated eicosapentaenoic acid - a mammalian DNA polymerase inhibitor. Int. J. Oncol. 36, 577-584 (2010
176. Chen, X. et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 68, 3169-3177 (2008
177. Weiss, G. J. et al. Final results from a phase 1 study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexedin patients with refractory cancer. J. Clin. Oncol. Abstr. 2576 (2010
178. Madhusudan, S. et al. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res. 33, 4711-4724 (2005 (Pubitemid 41418873)
179. Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet 376, 235-244 (2010
180. Samol, J. et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest. New Drugs 30, 1493-1500 (2012
181. Khan, O. A. et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br. J. Cancer 104, 750-755 (2011
182. Patel, A. G., De Lorenzo, S., Flatten, K., Poirier, G. & Kaufmann, S. H. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin. Cancer Res. 18, 1655-1662 (2012
183. Kuschal, C. et al. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition. Exp. Dermatol. 20, 795-799 (2011
184. Prewett, M. et al. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin. Cancer Res. 13, 7432-7440 (2007
185. Kruszewski, M., Wojewodzka, M., Iwanenko, T., Szumiel, I. & Okuyama, A. Differential inhibitory effect of OK 1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Mutat. Res. 409, 31-36 (1998 (Pubitemid 28464459)
186. Ismail, I. H. et al. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 23, 873-882 (2004 (Pubitemid 38250932)
187. Huang, F. et al. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem. Biol. 6, 628-635 (2011
188. Rainey, M. D., Charlton, M. E., Stanton, R. V. & Kastan, M. B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 68, 7466-7467 (2008
189. Golding, S. E. et al. Improved ATM kinase inhibitor KU 60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 8, 2894-2902 (2009
190. Hirai, H. et al. Small-molecule inhibition of Wee1 kinase by MK 1775 selectively sensitizes p53 deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 8, 2992-3000 (2009
191. Rajeshkumar, N. V. et al. MK 1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53 deficient pancreatic cancer xenografts Clin. Cancer Res. 17, 2799-2806 (2011
192. Kreahling, J. M. et al. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol. Cancer Ther. 11, 174-182 (2012
193. Schellens, J. H. M. et al. Update on a phase I pharmacologic and pharmacodynamic study of MK 1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J. Clin. Oncol. Abstr. 29, 3068 (2011
194. Brezak, M. C. et al. IRC 083864, a novel bisquinone inhibitor of CDC25 phosphatases active against human cancer cells. Int. J. Cancer 124, 1449-1456 (2009
195. Lavecchia, A., Di Giovanni, C. & Novellino, E. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Expert Opin. Ther. Patents 20, 405-425 (2010
196. Jobson, A. G. et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7 nitro 1H indole-2 carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]- phenyl}-amide]. J. Pharmacol. Exp. Ther. 331, 816-826 (2009
197. Swisher, E. M. et al. Secondary Brca1 mutations in Brca1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008). (Pubitemid 351556255)